A polymorphism in NAD(P)H:quinone oxidoreductase (NQO1): relationship of a homozygous mutation at position 609 of the NQO1 cDNA to NQO1 activity Sir -NQO1 has attracted considerable attention owing to its ability to deactivate a broad range of xenobiotics while activating certain anti-tumour quinones (Ross et al., 1994) . A number of recent reports have highlighted the occurrence and potential significance of a point mutation in the NQO1 gene which is associated with a loss of NQO1 activity in both normal and tumour tissue (Traver et al., 1992; Eickelmann et al., 1994a,b; Rosvold et al., 1995; Kolesar et al., 1995) . The mutation is a C to T point mutation at position 609 of the NQO1 cDNA which codes for a proline to serine substitution in the amino acid sequence of the protein (Traver et al., 1992) . The mutation was originally characterised in the BE human colon adenocarcinoma cell line by SSCP analysis and sequencing (Traver et al., 1992) and subsequently in the H596 human non-small-cell lung cancer cell line by a polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) technique (1995) have recently examined the relationship between the heterozygous mutation at position 609 and NQO1 activity. These data demonstrate a wide range of NQO1 activity in IC to T heterozygotes and suggests a significant role for post-transcriptional modification in determination of NQO1 activity.
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In the paper by Kuehl et al. (1995) , the BE cell line is described as heterozygous for the 9C-T point mutation with very low NQO1 activity. An additional fibroblastoid cell line, the 3701T line, was reported as homozygous for the mutation with very low NQO1 activity. Since these results differed, with respect to the BE cell line, from the original report of Traver et al. (1992) al., 1992, 1995) . The same conclusion was reached by Eickelmann et al. (1994) who reported that a cell line and three human kidney carcinoma samples without detectable NQO1 activity were all homozygous for the IC to T mutation.
An alternatively spliced form of NQO1 lacking exon 4 and the quinone binding site has recently been reported (Gasdaska et al., 1995) . This form of NQO1 has minimal enzyme activity with traditional model substrates for NQO1 but retains immunoreactivity and can be detected using a polyclonal antibody to NQO1 (Gasdaska et al., 1995) . We have also examined BE and H596 cells for NQO1 protein using the same polyclonal antibody used by Gasdaska and colleagues and were unable to detect NQO1 protein. We have recently suggested a different form of alternate splicing as a possible explanation for the appearance of marked NQO1 activity in a fibroblastoid cell line, G38-8X, in the absence of detectable protein by immunoblot analysis (Kuehl et al., 1996) . We reasoned that an alternatively spliced form of NQO1 might retain catalytic activity but have lost the epitope required for immunoreactivity with the antibody against NQO1 (Kuehl et al., 1996) . This would not be a plausible explanation for the lack of NQO1 protein in homozygous 609C to T mutants since these cells are essentially devoid of both NQO1 immunoreactivity and NQO1 activity.
In conclusion, although a heterozygous C to T mutation at position 609 of the NQO1 cDNA may be associated with widely differing NQOl activities, the presence of a homozygous C -T mutation at position 609 results in a loss of NQO1 protein and activity. The homozygous mutation represents a polymorphism in NQO1 which may be of significance since its prevalence in various populations has been reported to be between 6% and 17% (Rosvold et al., 1995; Kuehl et al., 1995; Eickelmann et al., 1994a; . The role of this polymorphism with respect to impaired protection from xenobiotic toxicity is under investigation 
